



# ESMO Preceptorship on Lung Cancer

## PROGRAMME

## ESMO PRECEPTORSHIP

**LISBON PORTUGAL**  
**17-18 NOVEMBER 2023**

### **Co-Chairs**

Rafal Dziadziuszko, Poland  
Pilar Garrido López, Spain

# ESMO PRECEPTORSHIP PROGRAMME

## LUNG CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Lisbon, Portugal  
17-18 November 2023

---

**CO-CHAIRS** Rafal Dziadziuszko, Poland  
Pilar Garrido López, Spain

**SPEAKERS** Anne-Marie Dingemans, Netherlands  
Enriqueta Felip, Spain  
Rosario García Campelo, Spain  
Lizza Hendriks, Netherlands  
Fernando López-Ríos, Spain  
Jarushka Naidoo, Ireland  
David Planchard, France  
Witold Rzyman, Poland

---

### LEARNING OBJECTIVES

- To learn the principles of pathology, molecular testing, and screening of lung cancer
- To understand current landscape of multimodality treatment of stage I - III lung cancer
- To understand the complex picture of immunotherapy and targeted therapies for lung cancer in 2023
- To familiarize with current treatment paradigms in SCLC, mesothelioma, and thymoma/thymic carcinoma

---

### ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 17 November 2023

<b>09:00-09:10</b> 10'	<b>Welcome and introduction</b>	<b>Rafal Dziadziuszko, PL</b> <b>Pilar Garrido López, ES</b>
<b>09:10-10:40</b> 90'	<b>SESSION 1</b> <b>Pathology, molecular testing, and screening of lung cancer</b>	<b>Chair:</b> <b>Pilar Garrido López, ES</b>
20'	Primer of pathology in thoracic malignancies	Fernando López-Ríos, ES
20'	Principles of molecular testing in lung cancer (tissue, liquid)	Fernando López-Ríos, ES
20'	Lung cancer screening	Witold Rzyman, PL
20'	Smoking cessation	Lizza Hendriks, NL
10'	Discussion	All
<b>10:40-11:10</b>	<b>Coffee break</b>	
<b>11:10-13:10</b> 120'	<b>SESSION 2</b> <b>Multimodality treatment of stage I - III NSCLC</b>	<b>Chair:</b> <b>Pilar Garrido López, ES</b>
25'	Principles of surgical management	Witold Rzyman, PL
5'	Discussion	All
25'	Principles of radiotherapy	Rafal Dziadziuszko, PL
5'	Discussion	All
25'	Principles of systemic treatment (adjuvant, neoadjuvant)	Rosario García Campelo, ES
5'	Discussion	All
25'	Ongoing clinical trials in operable NSCLC	Rafal Dziadziuszko, PL
5'	Discussion	All
<b>13:10-14:10</b>	<b>Lunch</b>	
<b>14:10-16:10</b> 120'	<b>SESSION 3</b> <b>Systemic treatment in non-oncogene-addicted NSCLC</b>	<b>Chair:</b> <b>Rafal Dziadziuszko, PL</b>
25'	Immunotherapy / Chemo-immunotherapy	Rosario García Campelo, ES
5'	Discussion	All
25'	Immunotherapy complications	Enriqueta Felip, ES
5'	Discussion	All
25'	Oligometastatic NSCLC	Anne-Marie Dingemans, NL
5'	Discussion	All
25'	Approach to patients with brain metastases	Lizza Hendriks, NL
5'	Discussion	All
<b>16:10-16:40</b>	<b>Coffee break</b>	

<b>16:40-18:40</b> 120'	<b>SESSION 4</b> <b>Oncogene-addicted NSCLC</b>	<b>Chair:</b> <b>Rafal Dziadziuszko, PL</b>
25'	How do I treat patients with EGFR mutations?	Pilar Garrido López, ES
5'	Discussion	All
25'	How do I treat patients with gene fusions?	David Planchard, FR
5'	Discussion	All
25'	How do I treat patients with HER2 mutations, BRAF mutations, MET mutations?	David Planchard, FR
5'	Discussion	All
25'	Novel targets (KRAS and others)	Pilar Garrido López, ES
5'	Discussion	All
<b>20:30</b>	<b>Dinner</b>	

## Saturday, 18 November 2023

<b>09:00-10:30</b> 90'	<b>SESSION 5</b> <b>Thoracic MDT with audience participation</b>	<b>Chair:</b> <b>Rafal Dziadziuszko, PL</b>
90'	Clinical case presentations from the audience (6x15')	All
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-13:00</b> 120'	<b>SESSION 6</b> <b>SCLC and other thoracic malignancies</b>	<b>Chair:</b> <b>Pilar Garrido López, ES</b>
25'	Principles of follow-up after treatment of thoracic malignancies	Enriqueta Felip, ES
5'	Discussion	All
25'	Current management of SCLC	Anne-Marie Dingemans, NL
5'	Discussion	All
25'	Current management of mesothelioma	Jarushka Naidoo, IE
5'	Discussion	All
25'	Current management of thymoma / thymic carcinoma	Jarushka Naidoo, IE
5'	Discussion	All
<b>13:00-13:15</b> 15'	<b>Conclusion and farewell</b>	<b>Rafal Dziadziuszko, PL</b> <b>Pilar Garrido López, ES</b>
<b>13:15-14:15</b>	<b>Lunch</b>	

**Note:** Each 15 min slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion